Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

COVID-19 Vaccine Efficacy & Safety Discussed at Town Hall

Ruth Jessen Hickman, MD  |  August 20, 2021

At a recent ACR town hall, panelists described immune responses and side effects of COVID-19 vaccination in patients with rheumatic disease, along with ways to leverage monoclonal antibody treatments, especially in light of virus variants.

Filed under:American College of Rheumatology Tagged with:COVID-19immunosuppressionvaccination

Healthcare Extenders Can Reduce Physician Burden & Improve Patient Access & Care

Kimberly Steinbarger, PT, MHS, DHSc, & Saba Mohiuddin, PharmD, BCACP  |  August 11, 2021

In the early 1900s, the treatment for rheumatic and musculoskeletal disease (RMD) was primarily targeted at symptomatic relief and included analgesics, physical therapy, splinting and bed rest. With the discovery of methotrexate and its impact on rheumatoid arthritis (RA) management, a much-needed evolution of medications targeting disease activity began. Over the past 30 years, several…

Filed under:Interprofessional PerspectiveWorkforce Tagged with:Advanced Practice CliniciansAssociation of Rheumatology Professionals (ARP)dietitiannurse practitioneroccupational therapistspharmacistphysical therapistphysician assistantssocial worker

Georgia Bonney

Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

Larry Beresford  |  August 6, 2021

As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

Filed under:Legislation & AdvocacyPractice Support Tagged with:Advocacyprior authorization

Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).

Filed under:Drug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:baricitinibEULARJAK inhibitorjakinibJanus Kinase InhibitorsRheumatoid Arthritis (RA)Tofacitinib

Treatment Factors to Consider in Patients with JIA

Jason Liebowitz, MD, FACR  |  July 18, 2021

Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.

Filed under:ConditionsMeeting Reports Tagged with:JIAjuvenile idiopathic arthritis (JIA)Pediatric RheumatologyPediatric Rheumatology SymposiumPRSYMTreatment

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

Achieving Excellence in Pediatric Rheumatology Clinical Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

PRSYM—At its heart, the practice of medicine in all forms is specifically centered on delivering compassionate, thoughtful and evidence-based clinical care. In the world of pediatric rheumatology, a range of issues, such as chronic pain, reproductive health and transitioning to adult providers, are of utmost importance to patients and physicians alike. These topics were addressed…

Filed under:ConditionsMeeting ReportsPain SyndromesPediatric Conditions Tagged with:Chronic painpatient carePediatricPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMreproductive healthtransition

Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

Jason Liebowitz, MD, FACR  |  July 16, 2021

JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.

Filed under:ConditionsMeeting Reports Tagged with:eyesJIA-associated uveitisjuvenile idiopathic arthritis (JIA)lungsPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMsJIAsJIA-associated lung disease

Early & Long-Term Remission of Spondyloarthritis

Jason Liebowitz, MD, FACR  |  July 16, 2021

Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting Reports Tagged with:EULARpatient carespondyloarthritis

Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination

Linda Carroll  |  July 12, 2021

(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…

Filed under:Conditions Tagged with:COVID-19FlaresSARS-CoV-2Systemic Rheumatic Diseasesvaccinationvaccine

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences